Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. That said, here are three stocks where Wall Street’s positive outlook is supported by strong fundamentals.
Netflix (NFLX)
Consensus Price Target: $114.66 (24.8% implied return)
Launched by Reed Hastings as a DVD mail rental company until its famous pivot to streaming in 2007, Netflix (NASDAQ: NFLX) is a pioneering streaming content platform.
Why Should NFLX Be on Your Watchlist?
- Global Streaming Paid Memberships are rising, meaning the company can increase revenue without incurring additional customer acquisition costs if it can cross-sell additional products and features
- Disciplined cost controls and effective management resulted in a strong two-year EBITDA margin of 30.4%, and it turbocharged its profits by achieving some fixed cost leverage
- Free cash flow margin expanded by 16.2 percentage points over the last few years, providing additional flexibility for investments and share buybacks/dividends
At $91.89 per share, Netflix trades at 22x forward EV/EBITDA. Is now a good time to buy? See for yourself in our full research report, it’s free.
Ollie's (OLLI)
Consensus Price Target: $138.53 (54.6% implied return)
Often located in suburban or semi-rural shopping centers, Ollie’s Bargain Outlet (NASDAQ: OLLI) is a discount retailer that acquires excess inventory then sells at meaningful discounts.
Why Are We Fans of OLLI?
- Offensive push to build new stores and attack its untapped market opportunities is backed by its same-store sales growth
- Locations open for at least a year are seeing increased demand as same-store sales have averaged 3.2% growth over the past two years
- Notable projected revenue growth of 13.4% for the next 12 months hints at market share gains
Ollie's is trading at $89.60 per share, or 20.5x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Vertex Pharmaceuticals (VRTX)
Consensus Price Target: $548.39 (28.1% implied return)
Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ: VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management.
Why Could VRTX Be a Winner?
- 14.1% annual revenue growth over the last five years surpassed the sector average as its offerings resonated with customers
- Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends
- Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures
Vertex Pharmaceuticals’s stock price of $428.00 implies a valuation ratio of 22.4x forward P/E. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
